Large-scale analysis of CoVIC antibodies by a global consortium identifies predictors of <i>in vivo</i>protection

Abstract The Coronavirus Immunotherapeutic Consortium (CoVIC) was established to develop prevention and therapeutic strategies against SARS-CoV-2 that could be used in low- middle-income countries. CoVIC compiled a unique panel comprising nearly 400 candidate antibodies contributed by 60 groups industry, academic, government settings. All the were first blinded at headquarters La Jolla Institute for Immunology through assignment of code name. Identical sets then sent under assigned names seven different partner reference labs carried out side-by-side, standardized analyses binding affinity, epitope location, high resolution structures, pseudovirus authentic virus neutralization, vivo protection, Fc-mediated effector functions. deposited their data, which validated made publicly accessible, database (CoVIC-DB). Using various statistical we investigated relationships among functional properties antibodies. For example, discern affinity full-length spike is more predictive neutralization potency than RBD, location together correlates with neutralization. However, alone not sufficient explain protection K18 mouse model infection, as other factors such antibody pharmacokinetics also important. Overall, results this study revealed important insights into are good predictors COVIC-19 Therapeutics Accelerator (a partnership Bill Melinda Gates Foundation), Foundation, Mastercard, Wellcome Trust, National Allergy Infectious Diseases Institutes Health, GHR FastGrant from Emergent Ventures